{"schema_version":"1.0","type":"article","title":"默沙東首付 4,700 萬美元的 ADC，胃癌又贏一次","url":"https://drugnews.com.tw/articles/2026-11-21-merck-kelun-trop2-adc-gastric-phase3-os.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-21-merck-kelun-trop2-adc-gastric-phase3-os.md","lang":"zh-Hant","date":"2026-11-21","publish_at":"2026-11-21T20:00:00+08:00","updated_at":"2026-11-21","category":"商業分析系列","topic":"BD / 授權","tags":["ADC","TROP2","胃癌","腫瘤","授權"],"summary":"默沙東向科倫博泰取得大中華區以外的開發與商業化權利。這次胃食道腺癌全球三期達到總生存期主要終點，無惡化存活期未達標。原始協議和後續年報揭露了簽約款及已收到的臨床里程碑款。","key_points":["TroFuse-015 的總生存期達標，無惡化存活期未達標。","科倫博泰兩筆不可退還的簽約款合計 4,700 萬美元，實收里程碑另計。","台灣院所列入試驗，台灣的開發及商業化權利由科倫博泰保留。"],"facts":[],"sections":["01｜病人活得更久，影像上的指標卻沒過關","02｜4,700 萬美元只算簽約款","03｜同樣瞄準 TROP2，存活結果各有一套證據","04｜買方看的是下一個適應症能否獨立成立","參考資料"],"references":[{"title":"TroFuse-015 胃食道腺癌最終分析公告","source":"默沙東","date":"2026-11-20","url":"https://www.merck.com/news/merck-announces-trofuse-015-trial-evaluating-sacituzumab-tirumotecan-sac-tmt-met-primary-endpoint-of-overall-survival-os-in-third-line-or-later-locally-advanced-unresectable-or-metastatic-gastroes/"},{"title":"TroFuse-015（NCT06356311）試驗登錄","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT06356311"},{"title":"TroFuse-005 子宮內膜癌三期讀出與美國審查","source":"默沙東","date":"2026-10-26","url":"https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/"},{"title":"MK-2870-015 三期設計與分層","source":"研究團隊／Annals of Oncology","date":"2024-09-14","url":"https://www.annalsofoncology.org/article/S0923-7534%2824%2903056-4/fulltext"},{"title":"項目 A 授權修正案及商務條款","source":"科倫藥業／巨潮資訊網","date":"2022-05-16","url":"https://static.cninfo.com.cn/finalpage/2022-05-16/1213362525.PDF"},{"title":"項目 A 身分確認（SKB264","source":"科倫藥業／巨潮資訊網","date":"2022-08-05","url":"https://static.cninfo.com.cn/finalpage/2022-08-05/1214223232.PDF"},{"title":"SKB264 授權地域與里程碑公告","source":"科倫博泰／港交所","date":"2024-02-23","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0223/2024022300306.pdf"},{"title":"2023 年報管理層討論：已付 SKB264 專案里程碑","source":"科倫博泰／港交所","date":"2024-04-18","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0418/2024041802054.pdf"},{"title":"2023 年度報告摘要：確認臨床里程碑已收","source":"科倫藥業／巨潮資訊網","date":"2024-04-25","url":"https://static.cninfo.com.cn/finalpage/2024-04-25/1219802086.PDF"},{"title":"2024 年中期報告：不同合作管線的里程碑收入","source":"科倫博泰／港交所","date":"2024-09-19","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0919/2024091900529.pdf"},{"title":"2023 Form 10-K：行使選擇權、技轉及研發資金","source":"默沙東／SEC","date":"2024-02-26","url":"https://www.sec.gov/Archives/edgar/data/310158/000162828024006850/R13.htm"},{"title":"2026 年中期業績：正式揭露保留地域與合作範圍","source":"科倫博泰／港交所","date":"2026-08-17","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701363.pdf"},{"title":"ASCENT 隨機三期原始結果","source":"研究團隊／New England Journal of Medicine","date":"2021-04-22","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2028485"},{"title":"TROPION-Breast01 的 PFS 與最終 OS","source":"美國 FDA","date":"2025-01-17","url":"https://www.fda.gov/drugs/cancer-approvals/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast"},{"title":"TROPION-Breast01 最終總生存期分析","source":"研究團隊／Annals of Oncology","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/41448362/"},{"title":"TAGS 三期試驗原始結果","source":"研究團隊／Lancet Oncology","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/30355453/"},{"title":"2026 第三季 10-Q：子宮內膜癌優先審查","source":"默沙東","date":"2026-11-04","url":"https://www.merck.com/wp-content/uploads/sites/124/2026/10/MRK-11.04.2026-10Q.pdf"},{"title":"SKB264 細胞內化與載荷釋放","source":"Frontiers in Oncology","date":"2022-12-23","url":"https://pubmed.ncbi.nlm.nih.gov/36620535/"},{"title":"本文為產業與公司分析，不構成投資或醫療建議。","source":"","date":"","url":""}],"images":[{"alt":"473 人 · 晚期胃食道腺癌","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/inline-card-number-a940b9a3caa6.png"},{"alt":"圖1｜TROP2 ADC 的細胞內遞送","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/figure-01.png"},{"alt":"圖2｜TroFuse-015 的試驗設計與結果","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/figure-02.png"},{"alt":"圖3｜默沙東的付款與科倫博泰保留的權利","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/figure-03.png"},{"alt":"5 所台灣院所 · 試驗登錄","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/inline-card-number-8d4f59572d6c.png"},{"alt":"圖4｜三項 TROP2 ADC 三期的主要讀數","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/figure-04.png"},{"alt":"中位總生存期 · 5.7 個月 · trifluridine/tipiracil 組 · 3.6 個月 · 安慰劑組","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/inline-card-comparison-3b13ec474603.png"},{"alt":"19.0 個月 · 子宮內膜癌的中位總生存期 · 12.1 個月 · 醫師選擇的對照組","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/inline-card-comparison-a5b185eb0692.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-21）。默沙東首付 4,700 萬美元的 ADC，胃癌又贏一次。https://drugnews.com.tw/articles/2026-11-21-merck-kelun-trop2-adc-gastric-phase3-os.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「TroFuse-015 的總生存期達標，無惡化存活期未達標」有哪些關鍵變化？","a":"TroFuse-015 的總生存期達標，無惡化存活期未達標。"},{"q":"「科倫博泰兩筆不可退還的簽約款合計 4,700 萬美元，實收里程碑另計」有哪些關鍵變化？","a":"科倫博泰兩筆不可退還的簽約款合計 4,700 萬美元，實收里程碑另計。"},{"q":"「台灣院所列入試驗，台灣的開發及商業化權利由科倫博泰保留」有哪些關鍵變化？","a":"台灣院所列入試驗，台灣的開發及商業化權利由科倫博泰保留。"}]}